/PRNewswire/ Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company, today announced that it has been selected by the American Society for.
/PRNewswire/ Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company today announced that it has been selected by the American Society of.
email article
Two commonly used thiotepa-based conditioning regimens were associated with favorable outcomes among patients with primary central nervous system lymphoma (PCNSL) undergoing autologous hematopoietic cell transplant (AHCT), according to a retrospective observational study.
Patients in the thiotepa/busulfan/cyclophosphamide (TBC) cohort and those in the thiotepa/carmustine (TT-BCNU) cohort had 3-year adjusted progression-free survival (PFS) rates of 75% and 76%, respectively, which were substantially higher than the PFS rate of 58% in a cohort that received carmustine/etoposide/cytarabine/melphalan (BEAM). Our findings suggest that thiotepa-containing regimens should be considered the standard in patients with PCNSL wherein AHCT is determined to be the consolidation of choice, wrote Michael Scordo, MD, of Memorial Sloan Kettering Cancer Center in New York City, and colleagues in